Syngene tests investor appetite for IPO

Parent Biocon hopes the CRO's strong growth profile and expansion plans will mitigate recent downturn in the Indian equity market

Syngene tests investor appetite for IPO

Indian pharma company Biocon has begun pre-marketing an initial public offering of its clinical research arm, Syngene, with a target fundraising of $100 million to $150 million. 

The group hopes the unit's strong growth profile will overcome investors' negativity towards the Indian stock market, which has been on a downturn since late January. After an extremely strong rally following the election of Narendra Modi last spring, the BSE Sensex topped out on January...

To continue reading, please login or register for free

Click for more on: ipo | india | credit suisse | jefferies | axis | karvy | pharma

Print Edition

FinanceAsia Print Edition